Search This Blog

Wednesday, November 8, 2023

Atara MS therapy misses primary endpoint in Phase 2

 Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achieved

Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program with Focusing of Resources and Planned Expense Reductions Expected to Extend Cash Runway Beyond Q3 2025

Allogeneic CAR-T Portfolio Advancing with Several Catalysts Anticipated in the Next 18 Months

https://www.businesswire.com/news/home/20231108902565/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.